Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407901 | 0.78 | ANPEP (0.33) | ANPEPPLAUIDO1 | |
| SCHEMBL6962983 | 0.78 | ANPEP (0.33) | ANPEPPLAUIDO1 | |
| SCHEMBL3653495 | 0.75 | PLAU (0.41) | ANPEPPLAUIDO1PDPK1TSHR | |
| SCHEMBL2183528 | 0.75 | PDPK1 (0.37) | PLAUIDO1PDPK1TSHRMTNR1A | |
| SCHEMBL1634692 | 0.72 | CYP11B2 (0.41) | PLAUMTNR1AMTNR1B | |
| SCHEMBL4769652 | 0.71 | PNMT (0.37) | ANPEPPLAUIDO1PDPK1MTNR1A | |
| SCHEMBL10390219 | 0.71 | HTR1A (0.37) | PLAUPDPK1MTNR1AMTNR1B | |
| SCHEMBL5714371 | 0.71 | PRCP (0.36) | PLAUIDO1PDPK1MTNR1AMTNR1B | |
| SCHEMBL9067653 | 0.71 | HTR1A (0.37) | PLAUPDPK1MTNR1AMTNR1B | |
| SCHEMBL7980704 | 0.69 | PRCP (0.39) | PLAUPDPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838934-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1890696-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | claimed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | claimed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | claimed |
| WO-2006130416-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | claimed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | claimed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| EP-2938341-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2938341-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-5451608-A | 2-amino-1,2,3,4-tetrahydronaphthalene derivatives active on the cardiovasular system, processes for their preparation and pharmaceutical compositions containing them | ZAMBON GROUP S.P.A. (IT) | 1995-09-19 | — | — | US | disclosed |
| US-5407956-A | Hypotensive agents, kidney disorders | ZAMBON GROUP S.P.A. (IT) | 1995-04-18 | — | — | US | disclosed |
| WO-1995007885-A1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.P.A. (IT) | 1995-03-23 | — | — | WO | disclosed |
| EP-0585440-A1 | 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES ACTIVE ON THE CARDIOVASCULAR SYSTEM, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | ZAMBON SPA (IT) | 1994-03-09 | — | — | EP | disclosed |
| WO-1993019036-A1 | 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES ACTIVE ON THE CARDIOVASCULAR SYSTEM, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAMBON GROUP S.P.A. (IT) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | ANPEP 4776/4885PLAU 4830/4885SLC18A3 2309/4885 |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | ANPEP 3058/4885PLAU 2723/4885SLC18A3 275/4885 |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | ANPEP 2366/4885PLAU 4599/4885SLC18A3 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.